[The role of anidulafungin therapy in solid organ transplant recipients].
Anidulafungin is a new echinocandin recently approved for the treatment of esophageal candidiasis, candidemia and other forms of invasive candidiasis, such as peritonitis and intra-abdominal abscesses in non-neutropenic patients. It is fungicidal against Candida spp. and fungistatic against Aspergillus spp. It is active against Pneumocystis jirovecii. In contrast, anidulafungin does not have activity against Cryptococcus neoformans, Zygomycetes or molds, other than Aspergillus spp. The drug is well tolerated, even in patients with renal or hepatic impairment. In contrast to other echinocandins, it does not significantly interfere with the cytochrome P450 pathway and has a low drug-drug interaction profile, including calcineurinic agents and other drugs used in transplant recipients. So far, anidulafungin appears to have an excellent safety profile with few adverse events and it promises a special consideration in the management of fungal infections happening in transplant recipients.
Fortún Abete
Jesús
J
Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, Spain. fortun@mi.madritel.es
Martín-Dávila
Pilar
P
D000077612:Anidulafungin; D000935:Antifungal Agents / Q000627:therapeutic use*; D054714:Echinocandins / Q000627:therapeutic use*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000188:drug therapy*
D000935:Antifungal Agents; D054714:Echinocandins; D000077612:Anidulafungin